Programmatic Grants in Environments, Genes and Chronic Disease

Webinar for Applicants
December 9, 2014
Programmatic Grants in Environments, Genes and Chronic Disease: Objectives

- To support interdisciplinary programmatic research that improves our understanding of how environment-gene interactions or environment-microbiome-gene interactions contribute to both metabolic and immunologically-mediated non-communicable chronic diseases;

- To support interdisciplinary programmatic research on the etiology of chronic non-communicable disease that may ultimately contribute to the development of new intellectual property, research methodology (including new methods for measuring environmental exposures) and/or approaches for disease prevention or treatment; and

- To build interdisciplinary collaborations and foster Canadian expertise in order to elucidate the environmental and genetic origins of non-communicable chronic disease.
Relevant Research Areas

Four funding pools:

- Environment-microbiome-gene interactions in chronic non-communicable diseases.
- Environment-gene interactions in chronic, non-communicable, immunologically-mediated diseases (e.g. IBD, type 1 diabetes, celiac disease).
- Environment-gene interactions in chronic, non-communicable metabolic diseases (e.g. type 2 diabetes, NAFLD, obesity).
- Environment-gene interactions in chronic, non-communicable diseases related to reproduction, fetal and/or early childhood development.

All applications must be relevant to one of the funding pools, and the research must include at least one environmental factor and at least one genetic component and how these components interact to contribute to chronic non-communicable disease.
Funding Opportunity Details

The total amount available for this funding opportunity is $14M (~7 grants, $400,000 per year for up to 5 years). This funding is non-renewable.

Of this $14 M:

- Up to $2 M is available to fund a minimum of 1 application focusing on the role of environment-microbiome-gene interactions in chronic non-communicable diseases.
- Up to $2 M is available to fund a minimum of 1 application focusing on chronic non-communicable immunologically-mediated diseases (e.g. IBD, type 1 diabetes, celiac disease).
- Up to $2 M is available to fund a minimum of 1 application focusing on chronic non-communicable metabolic diseases (e.g. type 2 diabetes, NAFLD, obesity).
- Up to $2 M is available to fund a minimum of 1 application focused on chronic non-communicable diseases related to reproduction, fetal and/or early childhood development.

The top rated application in each funding pool will be funded, and then all applications in the competition will be pooled together and funded in rank order as far as the remaining $6 M will allow.
Applicants who are successful at the LOI stage will be required to participate in a Partners’ Forum in June, 2015.

The purpose of the forum is to provide opportunities for Applicants and Partners (representatives from voluntary health organizations, private sector organizations and other partners) to exchange information and ideas, with the overall goal of strengthening the full applications. The Forum will also help identify alignment of interests between researchers and Partners.

To facilitate this exchange of ideas, Partners will have access to reviewer comments and full LOI applications submitted by all Applicants successful at the LOI stage.

Partners will have access to full applications to conduct relevance review at the Full Application Stage.
Environments, Genes and Chronic Disease

Partners

CIHR Institute Collaborators
• Institute of Nutrition, Metabolism and Diabetes
• Institute of Aging
• Institute of Human Development, Child Youth and Health
• Institute of Infection and Immunity

External Partners*
• Canadian Association of Gastroenterology
• Crohn’s and Colitis Canada
• Cystic Fibrosis Canada
• Heart and Stroke Foundation
• Kidney Foundation of Canada

* INMD is seeking additional partners
## Important Dates

<table>
<thead>
<tr>
<th>Competition</th>
<th>201501EGC (Phase 1: Letter of Intent)</th>
<th>201509ECD (Phase 2: Application)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Deadline</td>
<td>January 20, 2015</td>
<td>September 17, 2015</td>
</tr>
<tr>
<td>Funding Start Date</td>
<td>January 1, 2016</td>
<td>January 1, 2016</td>
</tr>
</tbody>
</table>
Eligibility to Apply

- The Nominated Principal Applicant must be an independent researcher.
- The Nominated Principal Applicant must be registered at an eligible institution.
- The application must include at least one other Principal Applicant, who is an independent researcher with expertise in a different discipline than the Nominated Principal Applicant.
- The application must include a New Investigator (within the first 5 years of an academic appointment) and/or a Clinician Scientist as either a co-Applicant or co-Principal Applicant.
- The application must include researchers from at least 2 different institutions.
- The application must align with only one of the funding pools.
Evaluation Criteria

1. Impact of the Research (30%)

2. Originality of the Proposal (25%)
   - Value added through a “program” of research
   - Evidence of unique inter-disciplinary collaboration(s)

3. Research Approach (20%)

4. Applicant(s) (15%)
   - Evidence that applicants will engage researchers from multiple institutions and in different disciplines and
   - Integration of New Investigator(s) and/or Clinician-Scientist(s).

5. Environment for the Research (10%)
   - Mentoring New Investigators and/or Clinician Investigators;
   - Evidence of collaboration involving substantive contributions from all members.
Contact Information

For questions on CIHR funding guidelines, how to apply, and the peer review process contact:

Jeff Warren
Program Delivery Coordinator
Telephone: 613-948-2813
Email: jeff.warren@cihr-irsc.gc.ca

For questions about this initiative and research objectives contact:

Keeley Rose
Project Manager
Institute of Nutrition, Metabolism and Diabetes (INMD)
Telephone: 416-978-1331
Email: keeley.rose@sickkids.ca